Cost impact analysis in patients with moderate to severe rheumatoid arthritis who do not respond to a biological disease-modifying drug (b-DMARD) or a conventional synthetic disease-modifying drug (EscFAM). CIARA STUDY. A3921325
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: PFIZER, SLU
- Execution start: 16/11/2020
- End of execution: 28/02/2023
- IP: RAFAEL CALIZ CALIZ